{"id":"W4283315989","doi":"10.1097/01.hs9.0000843712.33707.fe","title":"S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Obinutuzumab; Internal medicine; Gastroenterology; Phases of clinical research; Follicular lymphoma; Progression-free survival; Refractory (planetary science); Randomized controlled trial; Surrogate endpoint; Surgery; Oncology; Clinical trial; Lymphoma; Chemotherapy; CD20","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001556561,0.001108552,0.001649866,0.0003092425,0.0002033923,0.0009897117,0.0007695653,0.0008546024,0.005320975],"category_scores_gemma":[0.0008133061,0.000457064,0.001230305,0.0003077108,0.0006866693,0.0006973101,0.0003344807,0.002199485,0.0008256654],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008701232,"about_ca_system_score_gemma":0.0009502012,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001046902,"about_ca_topic_score_gemma":0.004176693,"domain_scores_codex":[0.999541,0.0002743857,0.00001920854,0.00005901134,0.00003490323,0.00007147744],"domain_scores_gemma":[0.999594,0.00009854733,0.0001126237,0.00002558381,0.00001755298,0.0001516816],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9507349,0.004928449,0.001173711,0.0007229467,0.0009184818,0.00006704755,0.00007537317,0.0008457595,0.006200622,0.0001643619,0.001695425,0.03247287],"study_design_scores_gemma":[0.8101492,0.1793593,0.004953249,0.00006084424,0.001098835,0.0001198362,0.000046031,0.001055115,0.001350383,0.0002129059,0.001574855,0.00001945214],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99151,0.003617453,0.0002141843,0.0006252453,0.0002048173,0.0009800444,0.0007647552,0.0000923809,0.001991124],"genre_scores_gemma":[0.9938785,0.001649381,0.0004957296,0.0005257842,0.0001818408,0.000602001,0.0007045889,0.00001339385,0.001948723],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005320975,"threshold_uncertainty_score":0.01780039,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01326491986349082,"score_gpt":0.2789006242860502,"score_spread":0.2656357044225593,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}